Literature DB >> 26295204

Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in STZ-induced diabetic rats.

Alok Shiomurti Tripathi, Papiya Mitra Mazumder, Anil Vilasrao Chandewar.   

Abstract

BACKGROUND: The present study evaluates the possible mechanism of sildenafil citrate (SIL) for the attenuation of renal failure in diabetic nephropathic (DN) animals.
METHODS: Diabetic nephropathy was induced by a single dose of streptozotocin (STZ) (60 mg/kg, i.p.) and confirmed by assessing the blood and urine biochemical parameters on the 28th day of its induction. The selected DN animals were treated with glimepiride (0.5 mg/kg, p.o.) and SIL (2.5 mg/kg, p.o.) for a period of 6 weeks. Biochemical parameters in blood and urine were estimated after the 29th and 70th day of the protocol for the estimation of the effect of SIL. RESULT: There were significant alterations in the blood and urine biochemical parameters in STZ-treated groups which confirmed DN. There was a significant decrease in the triglyceride level in the SIL-only-treated group on the 70th day of the protocol. The histopathology study also suggested that SIL treatment results in the improvement in the podocyte count in DN animals.
CONCLUSIONS: The present study concludes that SIL improves the renal function by decreasing the triglyceride level and improving the podocyte count in DN animals.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26295204     DOI: 10.1515/jbcpp-2015-0035

Source DB:  PubMed          Journal:  J Basic Clin Physiol Pharmacol        ISSN: 0792-6855


  6 in total

1.  Anhuienoside C Attenuates Podocyte Injury in Diabetic Nephropathy Rats.

Authors:  Chengjian Wang; Yingsong Jiang; Keping Yu; Ke Liu; Hao Wang
Journal:  Dose Response       Date:  2020-09-22       Impact factor: 2.658

Review 2.  Sex-related differences in diabetic kidney disease: A review on the mechanisms and potential therapeutic implications.

Authors:  Federica Piani; Isabella Melena; Kalie L Tommerdahl; Natalie Nokoff; Robert G Nelson; Meda E Pavkov; Daniël H van Raalte; David Z Cherney; Richard J Johnson; Kristen J Nadeau; Petter Bjornstad
Journal:  J Diabetes Complications       Date:  2020-12-31       Impact factor: 2.852

3.  Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7.

Authors:  Riccardo Pofi; Daniela Fiore; Rita De Gaetano; Giuseppe Panio; Daniele Gianfrilli; Carlotta Pozza; Federica Barbagallo; Yang Kevin Xiang; Konstantinos Giannakakis; Susanna Morano; Andrea Lenzi; Fabio Naro; Andrea M Isidori; Mary Anna Venneri
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

Review 4.  Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review.

Authors:  Georgios Georgiadis; Ioannis-Erineos Zisis; Anca Oana Docea; Konstantinos Tsarouhas; Irene Fragkiadoulaki; Charalampos Mavridis; Markos Karavitakis; Stavros Stratakis; Kostas Stylianou; Christina Tsitsimpikou; Daniela Calina; Nikolaos Sofikitis; Aristidis Tsatsakis; Charalampos Mamoulakis
Journal:  J Clin Med       Date:  2020-04-29       Impact factor: 4.241

5.  Nephroprotective effect of Vanillic acid in STZ-induced diabetic rats.

Authors:  Savita Kumari; Anjoo Kamboj; Manish Wanjari; Anil Kumar Sharma
Journal:  J Diabetes Metab Disord       Date:  2021-04-03

6.  The effect of iloprost and sildenafil, alone and in combination, on myocardial ischaemia and nitric oxide and irisin levels.

Authors:  Suna Aydin; Tuncay Kuloglu; Suleyman Aydin; Meltem Yardim; Davut Azboy; Zeki Temizturk; Ali Kemal Kalkan; Mehmet Nesimi Eren
Journal:  Cardiovasc J Afr       Date:  2017-08-31       Impact factor: 1.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.